The short version of Preclinical study fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-03-19 and is reviewed periodically as new material appears.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Structural features include amino acid residues and a hexanoic acid group. |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Names vary by source and should be verified. |
| Origin | Angiotensin IV research | Developed as a modified analog in academic laboratories. |
| Primary research focus | Synaptic growth and cognition | Studied mainly in cultured neurons and rodent models. |
| Regulatory status | Not approved as a drug | No accepted human therapeutic or supplement status. |
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
=== Benefits of serum over plasma === Plasma preparation requires the addition of anticoagulants, which can cause expected and unexpected measurement errors. For example, anticoagulant salts can add extra cations like NH4+, Li+, Na+ and K+ to the sample, or impurities like lead and aluminum. Chelator anticoagulants like EDTA and citrate salts work by binding calcium (see carboxyglutamic acid), but they may also bind other ions. Even if such ions are not the analytes, chelators can interfere with enzyme activity measurements. For example, EDTA binds zinc ions, which alkaline phosphatases need as cofactors. Thus, phosphatase activity cannot be measured if EDTA is used. An unknown volume of anticoagulants can be added to a plasma sample by accident, which may ruin the sample as the analyte concentration is changed by an unknown amount. No anticoagulants are added to serum samples, which decreases the preparation cost of the samples relative to plasma samples. Plasma samples can form tiny clots if the added anticoagulant is not properly mixed with the sample. Non-uniform samples can cause measurement errors.
On 7 November, the National Guard warned of ceasefire violations such as the bombing of civilian homes, the National Guard also shot down a drone loaded with explosives. The statement added that there were clashes in Rasas. On 13 November, heavy fighting broke out in Al-Majdal, following the infiltration of Syrian government forces and drone attacks, prompting the National Guard to send reinforcements to the border. That same day, Syrian government forces attacked the Suwayda–Taara road, The skirmishes, which were the heaviest in months, were noticeable for the use of "drones, mortars, and heavy machine guns" by both sides. The "towns of Wolgha, Tal al-Aqra, Tal Hadid and al-Mazraa" were targeted by what the Syrian government called "outlaw forces". On 19 November, Benjamin Netanyahu visited the areas occupied by Israel in the invasion of Syria, where he declared he would "protect the Druze allies in Jabal al-Druze". On 20 November, a gang kidnapped five Druze people from Suwayda: Talal Dheeb, Reem Dheeb, Mahmouda Quraisha, Ilham Abu Zein Al-Din and Rafi Habib, who were released in Al-Musayfirah, Daraa Governorate. The gang leader was arrested. The kidnapped people were residents of As-Sawra as-Saghira. Hussam al-Tahhan stated that "the operation took place after careful monitoring on the ground and intensive surveillance and investigations".
=== Shutdown === On September 4, 2018, Theranos announced in an email to investors that it would cease operations and release its assets and remaining cash to creditors after all efforts to find a buyer were fruitless. Most of the company's remaining employees had been laid off on the previous Friday, August 31. However, Theranos general counsel and new CEO David Taylor and a few support staffers remained on payroll for a few more days. Any equity investments in the company were made worthless by the shutdown. Theranos would later transfer its patents to Fortress Investment Group on September 12 in exchange for Theranos's cash assets to be distributed to creditors.
== Diversity-oriented libraries == Even though combinatorial chemistry has been an essential part of early drug discovery for more than two decades, so far only one de novo combinatorial chemistry-synthesized chemical has been approved for clinical use by FDA (sorafenib, a multikinase inhibitor indicated for advanced renal cancer). The analysis of the poor success rate of the approach has been suggested to connect with the rather limited chemical space covered by products of combinatorial chemistry. When comparing the properties of compounds in combinatorial chemistry libraries to those of approved drugs and natural products, Feher and Schmidt noted that combinatorial chemistry libraries suffer particularly from the lack of chirality, as well as structure rigidity, both of which are widely regarded as drug-like properties. Even though natural product drug discovery has not probably been the most fashionable trend in the pharmaceutical industry in recent times, a large proportion of new chemical entities still are nature-derived compounds, and thus, it has been suggested that effectiveness of combinatorial chemistry could be improved by enhancing the chemical diversity of screening libraries. As chirality and rigidity are the two most important features distinguishing approved drugs and natural products from compounds in combinatorial chemistry libraries, these are the two issues emphasized in so-called diversity oriented libraries, i.e. compound collections that aim at coverage of the chemical space, instead of just huge numbers of compounds.
There is at least one and possibly two fossil specimens of the hadrosaur Edmontosaurus annectens with healed caudal injuries caused by Tyrannosaurus bites made while the herbivore was alive. One pair of Edmontosaurus caudal (tail) vertebrae has the tip of an adult Tyrannosaurus tooth embedded in the bone, with evidence of new bone growth that wrapped around the tooth, showing that this individual had also survived a Tyrannosaurus attack. Another specimen of Edmontosaurus (in some newspapers it was misidentified as Hadrosaurus) from Montana showed healed supposed tyrannosaur-inflicted damage on its tail vertebrae where some of its caudal neural spines was mutilated; however, in this case the damage is ambiguous and not directly attributable to Tyrannosaurus. There is also evidence for an aggressive interaction between a Triceratops and a Tyrannosaurus in the form of partially healed tyrannosaur tooth marks on a Triceratops brow horn and squamosal (a bone of the neck frill); the bitten horn is also broken, with new bone growth after the break. It is not known what the exact nature of the interaction was, though: either animal could have been the aggressor. Since the Triceratops wounds healed, it is most likely that the Triceratops survived the encounter and managed to overcome the Tyrannosaurus. In a battle against a bull Triceratops, the Triceratops would likely defend itself by inflicting fatal wounds to the Tyrannosaurus using its sharp horns.
Sources: en.wikipedia.org
==== Monoclonal antibodies ==== Monoclonal antibodies have long been considered for OI, but as of 2021, such therapy has not been approved for OI, neither in the European Union nor in the United States. Thus, it is unclear whether they are safe or effective. Among the monoclonal antibodies that have been studied are romosozumab (targets sclerostin, by Amgen), fresolimumab (TGF-β, Sanofi), blosozumab (sclerostin, Lilly), and setrusumab (sclerostin, begun by Novartis). Setrusumab, formerly known as BPS-804, is a monoclonal antibody that targets sclerostin, and has been studied in OI specifically more than any of the others. In the body, sclerostin binds to the LRP5 and LRP6 receptors, resulting in inhibition of the Wnt signaling pathway. This decreases bone formation, and is not a problem when a person has healthy bones. It is thought, though, that decreasing the concentration of sclerostin in the body may lead to the formation of more bone, and that is the premise as to why monoclonal antibodies that reduce the concentrations of naturally occurring sclerostin may help strengthen OI bone. While setrusumab was first developed at the pharmaceutical company Novartis, Novartis sold its rights to patent the drug to Mereo Biopharma in 2015, who has continued its development in conjunction with Ultragenyx. In 2019, Mereo announced that it had concluded collecting data for its phase II-B trial of setrusumab; the study was completed on 12 November 2020.
Curium is a synthetic chemical element; it has symbol Cm and atomic number 96. This transuranic actinide element was named after eminent scientists Marie and Pierre Curie, both known for their research on radioactivity. Curium was first intentionally made by the team of Glenn T. Seaborg, Ralph A. James, and Albert Ghiorso in 1944, using the cyclotron at Berkeley. They bombarded the newly discovered element plutonium (the isotope 239Pu) with alpha particles. This was then sent to the Metallurgical Laboratory at the University of Chicago where a tiny sample of curium was eventually separated and identified. The discovery was kept secret until after the end of World War II. The news was released to the public in November 1947. Most curium is produced by bombarding uranium or plutonium with neutrons in nuclear reactors – one tonne of spent nuclear fuel contains ~20 grams of curium. Curium is a hard, dense, silvery metal with a high melting and boiling point for an actinide. It is paramagnetic at ambient conditions, but becomes antiferromagnetic upon cooling, and other magnetic transitions are also seen in many curium compounds. In compounds, curium usually has valence +3 and sometimes +4; the +3 valence is predominant in solutions. Curium readily oxidizes, and its oxides are a dominant form of this element. It forms strongly fluorescent complexes with various organic compounds. If it gets into the human body, curium accumulates in bones, lungs, and liver, where it promotes cancer.
== Brumation == In the colder winter months, some rattlesnake species enter a period of brumation, which is dormancy similar to hibernation. They often gather for brumation in large numbers, sometimes over 1,000 snakes, and huddle together inside underground "rattlesnake dens" or hibernacula. They regularly share their winter burrows with a wide variety of other species (such as turtles, small mammals, invertebrates, and other types of snakes). Rattlesnakes often return to the same den every year, sometimes traveling several miles to get there. How the rattlesnakes find their way back to the dens each year is unknown, but it may involve a combination of pheromone trails and visual cues such as topography, celestial navigation, and solar orientation. Species with long periods of brumation tend to have much lower reproductive rates than those with shorter brumation periods or those that do not brumate at all. Female timber rattlesnakes in high peaks in the Appalachian Mountains of New England reproduce every three years on average; the lance-headed rattlesnake (C. polystictus), native to the warm climate of Mexico, reproduces annually. Like most other snakes, rattlesnakes aestivate during very hot or dry periods, which is why they are rarely seen during the hottest and driest months of summer.
Soy sauce is made either by fermentation or by hydrolysis. Some commercial sauces have both fermented and chemical sauces. Flavor, color, and aroma developments during production are attributed to non-enzymatic Maillard browning. Variation is usually achieved as the result of different methods and durations of fermentation, different ratios of water, salt, and fermented soy, or through the addition of other ingredients.
John Henderson Knox FRS (1927 – 15 October 2018) was a Professor of Physical Chemistry at the University of Edinburgh and is considered a distinguished contributor to the fields of reaction kinetics and chromatography.
Sources: en.wikipedia.org
Quechua people cultivate and eat a variety of foods. They domesticated potatoes, which originated in the region, and cultivated thousands of potato varieties, which are used for food and medicine. Climate change is threatening their potato and other traditional crops but they are undertaking conservation and adaptation efforts. Quinoa is another staple crop grown by the Quechua people. Ch’arki (the origin of the English word jerky) is a dried (and sometimes salted) meat. It was traditionally made from llama meat that was sun- and freeze-dried in the Andean sun and cold nights, but is now also often made from horse and beef, with variation among countries. Pachamanca, a Quechua word for a pit cooking technique used in Peru, includes several types of meat such as chicken, beef, pork, lamb, and/or mutton; tubers such as potatoes, sweet potatoes, yucca, uqa/ok’a (oca in Spanish), and mashwa; other vegetables such as maize/corn and fava beans; seasonings; and sometimes cheese in a small pot and/or tamales. Guinea pigs are also raised for meat. Other foods and crops include the meat of llamas and alpacas as well as beans, barley, hot peppers, coriander, and peanuts.
Insulin receptor substrate 1 (IRS-1) is a signaling adapter protein that in humans is encoded by the IRS1 gene. It is a 180 kDa protein with amino acid sequence of 1242 residues. It contains a single pleckstrin homology (PH) domain at the N-terminus and a PTB domain ca. 40 residues downstream of this, followed by a poorly conserved C-terminus tail. Together with IRS2, IRS3 (pseudogene) and IRS4, it is homologous to the Drosophila protein chico, whose disruption extends the median lifespan of flies up to 48%. Similarly, Irs1 mutant mice experience moderate life extension and delayed age-related pathologies.
== External links == Click Chemistry: Short Review and Recent Literature National Science Foundation: Feature "Going Live with Click Chemistry" Chemical and Engineering News: Feature "In-Situ Click Chemistry" Chemical and Engineering News: Feature "Copper-free Click Chemistry" Metal-free click chemistry review[link removed] Click Chemistry – a Chem Soc Rev themed issue highlighting the latest applications of click chemistry, guest edited by M. G. Finn and Valery Fokin. Published by the Royal Society of Chemistry
the bourgeois exploiters and the exploited proletariat; that capitalism employs nationalist war to further private economic expansion; that socialism is an economic system that voids social classes through public ownership of the means of production and so will eliminate the economic causes of war; and that once the state (socialist or communist) withers away, so shall international relations wither away because they are projections of national economic forces, Lenin said that the capitalists' exhaustion of domestic sources of investment profit by way of price-fixing trusts and cartels, then prompts the same capitalists to export investment capital to undeveloped countries to finance the exploitation of natural resources and the native populations and to create new markets. That the capitalists' control of national politics ensures the government's military safeguarding of colonial investments and the consequent imperial competition for economic supremacy provokes international wars to protect their national interests. In the vertical perspective (social-class relations) of Marxism–Leninism, the internal and international affairs of a country are a political continuum, not separate realms of human activity. This is the philosophic opposite of the horizontal perspectives (country-to-country) of the liberal and the realist approaches to international relations.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide-like compound studied primarily in preclinical models. It is often classified as an angiotensin IV analog and has been investigated for effects on neuronal connectivity. It is not an approved drug or dietary supplement.
The exact mechanism is uncertain. Some research proposes activation of hepatocyte growth factor/c-Met signaling, while other evidence implicates insulin-regulated aminopeptidase. Multiple pathways may contribute, depending on the experimental system.
Published large-scale human trials are lacking. Most available data come from cell cultures and animal studies. As a result, human safety, appropriate dosing, and clinical effectiveness are not established.
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.